Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

PURPOSE: Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). Depatuxizumab mafodotin (depatux-m), formerly ABT-414, is an antibody–drug conjugate that preferentially binds cells wit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Chemother Pharmacol
Autors principals: van den Bent, Martin, Gan, Hui K., Lassman, Andrew B., Kumthekar, Priya, Merrell, Ryan, Butowski, Nicholas, Lwin, Zarnie, Mikkelsen, Tom, Nabors, Louis B., Papadopoulos, Kyriakos P., Penas-Prado, Marta, Simes, John, Wheeler, Helen, Walbert, Tobias, Scott, Andrew M., Gomez, Erica, Lee, Ho-Jin, Roberts-Rapp, Lisa, Xiong, Hao, Bain, Earle, Ansell, Peter J., Holen, Kyle D., Maag, David, Reardon, David A.
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2017
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5686264/
https://ncbi.nlm.nih.gov/pubmed/29075855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3451-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars